The scientist’s investigation covers issues in Internal medicine, Genetics, Atrial fibrillation, Apixaban and Stroke. His Internal medicine study combines topics from a wide range of disciplines, such as Endocrinology, Surgery and Cardiology. His work on Mitochondrial DNA, Mutation, Point mutation and Episodic ataxia as part of general Genetics research is frequently linked to PRRT2, bridging the gap between disciplines.
His Atrial fibrillation research is multidisciplinary, incorporating perspectives in Randomized controlled trial, Proportional hazards model and Embolism. His Apixaban research is classified as research in Warfarin. His research integrates issues of Concomitant and Myocardial infarction in his study of Stroke.
Michael G. Hanna focuses on Internal medicine, Genetics, Pathology, Cardiology and Clinical neurology. His Internal medicine research includes elements of Endocrinology and Periodic paralysis. His work focuses on many connections between Atrial fibrillation and other disciplines, such as Stroke, that overlap with his field of interest in Proportional hazards model.
His Myotonia research includes themes of Channelopathy and Sodium channel. He combines subjects such as Ataxia, Neuroscience and Epilepsy with his study of Episodic ataxia. To a larger extent, he studies Warfarin with the aim of understanding Apixaban.
His main research concerns Internal medicine, Pathology, Cardiology, Myotonia and Atrial fibrillation. His work on Adverse effect as part of general Internal medicine study is frequently connected to In patient, therefore bridging the gap between diverse disciplines of science and establishing a new relationship between them. Bioinformatics is closely connected to Skeletal muscle in his research, which is encompassed under the umbrella topic of Pathology.
His Myotonia research incorporates elements of Channelopathy, Periodic paralysis and Sodium channel. While the research belongs to areas of Atrial fibrillation, Michael G. Hanna spends his time largely on the problem of Stroke, intersecting his research to questions surrounding Proportional hazards model. His research links Hazard ratio with Apixaban.
Michael G. Hanna mainly investigates Internal medicine, Atrial fibrillation, Cardiology, Apixaban and Stroke. His study in Endocrinology extends to Internal medicine with its themes. Michael G. Hanna has included themes like Mitral regurgitation, Sudden death, Incidence and Cause of death in his Atrial fibrillation study.
The study incorporates disciplines such as Diaphragmatic weakness, Lung volumes and Pulmonary function testing in addition to Cardiology. His Apixaban study is concerned with the larger field of Warfarin. His Stroke research integrates issues from Coagulation, Proportional hazards model, Heart failure and Fibrin.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Apixaban versus Warfarin in Patients with Atrial Fibrillation
Christopher B. Granger;John H. Alexander;Renato D. Lopes;Elaine M. Hylek.
The New England Journal of Medicine (2011)
Efficacy of apixaban when compared with warfarin in relation to renal function in patients with atrial fibrillation: insights from the ARISTOTLE trial.
Stefan H. Hohnloser;Ziad Hijazi;Laine Thomas;John H. Alexander.
European Heart Journal (2012)
Active specific immunotherapy for stage II and stage III human colon cancer: a randomised trial
Jan B Vermorken;Anke M E Claessen;Harm van Tinteren;Helen E Gall.
The Lancet (1999)
Apixaban for Reduction In Stroke and Other ThromboemboLic Events in Atrial Fibrillation (ARISTOTLE) trial: Design and rationale
Renato D. Lopes;John H. Alexander;Sana M. Al-Khatib;Jack Ansell.
American Heart Journal (2010)
Exercise Intolerance Due to Mutations in the Cytochrome b Gene of Mitochondrial DNA
Antoni L. Andreu;Michael G. Hanna;Heinz Reichmann;Claudio Bruno.
The New England Journal of Medicine (1999)
Human epilepsy associated with dysfunction of the brain P/Q-type calcium channel
Anne Jouvenceau;Anne Jouvenceau;Louise H Eunson;Alexander Spauschus;Alexander Spauschus;Venkataswaran Ramesh.
The Lancet (2001)
Phenotypic spectrum associated with mutations of the mitochondrial polymerase γ gene
R Horvath;G Hudson;G Ferrari;N Futterer.
A novel mutation in the human voltage-gated potassium channel gene (Kv1.1) associates with episodic ataxia type 1 and sometimes with partial epilepsy.
S. M. Zuberi;L. H. Eunson;A. Spauschus;R. De Silva.
Efficacy and safety of apixaban compared with warfarin according to age for stroke prevention in atrial fibrillation: observations from the ARISTOTLE trial.
Sigrun Halvorsen;Dan Atar;Dan Atar;Hongqiu Yang;Raffaele De Caterina.
European Heart Journal (2014)
Major Bleeding in Patients With Atrial Fibrillation Receiving Apixaban or Warfarin: The ARISTOTLE Trial (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation): Predictors, Characteristics, and Clinical Outcomes
Elaine M. Hylek;Claes Held;John H. Alexander;Renato D. Lopes.
Journal of the American College of Cardiology (2014)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: